|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 黄芪及其有效组分药理作用与临床应用现状显示文摘黄芪从古至今应用广泛,现代药理研究证明其主要有效组分黄芪多糖、黄芪总黄酮、黄芪甲苷等具有保护心血管、调节免疫、抗肿瘤、抗氧化应激、改善代谢等作用。疾病的发生多与免疫系统相关,而作为补气中药,黄芪对免疫系统有更大贡献。不仅单用有效,与西药及现代医学技术联用更能呈现出提高机体抗病原体能力。如抗肿瘤的免疫疗法及维持机体免疫平衡环境免受外界刺激带来的损害,这正体现了中医“扶正”的理念。在临床应用上,黄芪注射液的开发为更多疾病的治疗提供可能性。另有学者已开展了黄芪纳米粒干预脓毒症小鼠的基础研究。这暗示中药潜在的临床价值建立在改进治疗手段和开发新型制剂上。现对近几年黄芪及其组分的药理作用和临床应用现状进行总结,以期为黄芪临床应用开发提供新的研究思路和科学依据。 | 张瑞华 张静文 刘玲 石勇 钞婷 王川 王斌 刘继平 | 2021 | 陕西中医2021，42，8： | 108 |
| 2 | Clinical therapeutic strategies for early stage of diabetic kidney disease显示文摘Diabetic kidney disease(DKD) is the most common cause of chronic kidney disease, leading to end-stage renal disease and cardiovascular disease. The overall number of patients with DKD will continue to increase in parallel with the increasing global pandemic of type 2 diabetes. Based on landmark clinical trials, DKD has become preventable by controlling conventional factors, including hyperglycemia and hypertension, with multifactorial therapy; however, the remaining risk of DKD progression is still high. In this review, we show the importance of targeting remission/regression of microalbuminuria in type 2 diabetic patients, which may protect against the progression of DKD and cardiovascular events. To achieve remission/regression of microalbuminuria, several steps are important, including the early detection of microalbuminuria with continuousscreening, targeting HbA1c < 7.0% for glucose control, the use of renin angiotensin system inhibitors to control blood pressure, the use of statins or fibrates to control dyslipidemia, and multifactorial treatment. Reducing microalbuminuria is therefore an important therapeutic goal, and the absence of microalbuminuria could be a pivotal biomarker of therapeutic success in diabetic patients. Other therapies, including vitamin D receptor activation, uric acid-lowering drugs, and incretin-related drugs, may also be promising for the prevention of DKD progression. | Munehiro Kitada Keizo Kanasaki Daisuke Koya | 2014 | World Journal of Diabetes2014，5，3： | 12 |
| 3 | Capacity-need gap in hospital resources for varying mitigation and containment strategies in India in the face of COVID-19 pandemic显示文摘Background:Due to uncertainties encompassing the transmission dynamics of COVID-19,mathematical models informing the trajectory of disease are being proposed throughout the world.Current pandemic is also characterized by surge in hospitalizations which has overwhelmed even the most resilient health systems.Therefore,it is imperative to assess health system preparedness in tandem with need projections for comprehensive outlook.Objective:We attempted this study to forecast the need for hospital resources for one year period and correspondingly assessed capacity and tipping points of Indian health system to absorb surges in need due to COVID-19.Methods:We employed age-structured deterministic SEIR model and modified it to allow for testing and isolation capacity to forecast the need under varying scenarios.Projections for documented cases were made for varying degree of containment and mitigation strategies.Correspondingly,data on health resources was collated from various government records.Further,we computed daily turnover of each of these resources which was then adjusted for proportion of cases requiring mild,severe and critical care to arrive at maximum number of COVID-19 cases manageable by health care system of India.Findings:Our results revealed pervasive deficits in the capacity of public health system to absorb surge in need during peak of epidemic.Also,model suggests that continuing strict lockdown measures in India after mid-May 2020 would have been ineffective in suppressing total infections significantly.Augmenting testing to 1,500,000 tests per day during projected peak(mid-September)under social-distancing measures and current test to positive rate of 9.7%would lead to more documented cases(60,000,000 to 90,000,000)culminating to surge in demand for hospital resources.A minimum allocation of 13x,70x and 37x times more beds for mild cases,ICU beds and mechanical ventilators respectively would be required to commensurate with need under that scenario.However,if testing capacity is limited to 9,000,000 tests per day(current situation as of 19th August 2020)under continued social-distancing measures,documented cases would plummet significantly,still requiring 5x,31x and 16x times the current allocated resources(beds for mild cases,ICU beds and mechanical ventilators respectively)to meet unmet need for COVID-19 treatment in India. | Veenapani Rajeev Verma Anuraag Saini Sumirtha Gandhi Umakant Dash Shaffi Fazaludeen Koya | 2020 | Infectious Disease Modelling2020，5，1： | 3 |
| 4 | Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model显示文摘 | Kunio Hirata Shinji Kume Shin-ichi Araki Masayoshi Sakaguchi Masami Chin-Kanasaki Keiji Isshiki Toshiro Sugimoto Akira Nishiyama Daisuke Koya Masakazu Haneda Atsunori Kashiwagi Takashi Uzu | 2009 | Biochemical and Biophysical Research Communications2009，，1： | 2 |
| 5 | APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes:results of a prospective observational follow up study 显示文摘 | Araki S Koya D Makiishi T | 2003 | Diabetes Care2003，26，8： | 1 |
| 6 | Enhancement of glomerular hemeoxygenase-1 expression in diabetic rats显示文摘 | Hayashi K Haneda M Koya D | 2001 | Diabetes Res Clin Pract2001，52，2： | 1 |
| 7 | Hygiene measures considering actual distributions of microorganisms in Japanese households显示文摘 | Ojima M Toshima Y Koya E | 2002 | J Appl Microbiol2002，93，5： | 1 |
| 8 | Discrepancy in EBVDNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder显示文摘 | Shimizu H Saitoh T Koya H | | 0，，05： | 1 |
| 9 | Cellular mechanisms in the development and progression of diabetic nephropathy : activa- tion of the DAG-PKC-ERK pathway 显示文摘 | Haneda M Koya D Kikkawa R | 2001 | Am J Kidney Dis2001，38，41： | 1 |
| 10 | Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor显示文摘 | Ishii H Jirousek MR Koya D | 1996 | Science1996，272，： | 1 |
| 11 | Predictive effects of urinary liver-type fatty acid-binding protein for deterio- rating renal function and incidence of cardiovascular dis- ease in type 2 diabetic patients without advanced nephropathy显示文摘 | Araki S Haneda M Koya D | 2013 | Diabetes Care2013，36，5： | 1 |
| 12 | IL-10-treated dendritic cells decrease airway hyperresponsiveness and airway inflammation in mice显示文摘 | Koya T Matsuda H Takeda K | 2007 | J Allergy Clin Immunol2007，119，： | 1 |
| 13 | Protein kinase C activation and the development of diabetic complications显示文摘 | Koya D King GL | 1998 | Diabetes1998，47，： | 1 |
| 14 | Characterization of protein kinase Cβ isoform activation on the gene expression of transformig growth factor,extracellular matrix components,and protanoids in the glomeruli of diabetic rats显示文摘 | Koya D Jirousek MR Lin YW | 1997 | J Clin Invest1997，100，： | 1 |
| 15 | Acadaspora gerdenaii,and its sunanamorph Glomus lepratichum based upon 18S rDNA gene sequences显示文摘 | Hiromichi Sauako Koya augawara Masanoti salto phylogentic pisition of an arbuscular nyucorrizal fyngus | 1998 | Mycoscience1998，，39： | 1 |
| 16 | Bacterial contamination of Japanese households and related concern about sanitation显示文摘 | Ojima M Toshima Y Koya E | 2002 | Int J Environ Health Res2002，12，1： | 1 |
| 17 | Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rat显示文摘 | Isshiki K Haneda M koya D | 2000 | Diabetes2000，49，6： | 1 |
| 18 | Progression of diabetic nephropathy显示文摘 | Kikkawa R Koya D Haneda M | 2003 | J Am Kidney Dis2003，41，： | 1 |
| 19 | Overview of glucose signaling in mesangial cells in diabetic nephropathy显示文摘 | Haneda M Koya D Isono M | 2003 | J Am Soc Nephrol2003，，： | 1 |
| 20 | N-Acetyl-Seryl- Aspartyl-Lysyl-Proline Inhibits TGF-β-Mediated Plasminogen Activator Inhibitor-1 Expression via Inhibition of Smad Pathway in Human Mesangial Cells 显示文摘 | Kanasaki K Koya D Sugimoto T | 2003 | J Am Soc Nephrol2003，14，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员